|

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • The First Affiliated Hospital of Nanchang University1

Indications

  • Relapsed/Refractory1
  • Multiple Myeloma1
  • Cancer1

Other1 trial

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.